mirtazapine has been researched along with Psychoses in 23 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of mirtazapine as an adjunctive treatment of negative symptoms in patients with chronic schizophrenia via meta-analysis." | 8.91 | Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. ( Chiapelli, J; Fischer, BA; Himelhoch, S; Reese, C; Vidal, C, 2015) |
| " Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia and attenuated psychotic symptoms despite ongoing treatment with cognitive behavioural therapy and mirtazapine who was treated with adjunctive cannabidiol (CBD) in doses between 200 and 800 mg/day for 6 months." | 7.96 | Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. ( Amminger, GP; Berger, M; Li, E, 2020) |
| "To our knowledge, this is the second reported case of Status epilepticus that has been associated with the use of olanzapine, while only one report of seizures, but none of Status epilepticus connected to mirtazapine is found in the literature." | 7.75 | Status epilepticus in a patient treated with olanzapine and mirtazapine. ( Iacovides, A; Kaprinis, G; Nimatoudis, J; Sokolaki, S; Spyridi, S, 2009) |
| "Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors." | 6.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| "To assess the efficacy of mirtazapine as an adjunctive treatment of negative symptoms in patients with chronic schizophrenia via meta-analysis." | 4.91 | Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. ( Chiapelli, J; Fischer, BA; Himelhoch, S; Reese, C; Vidal, C, 2015) |
| " The most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (F0/G3), valproate and quetiapine in patients with disorders due to psychoactive substance use (F1), valproate in patients with psychotic disorders (F2), and risperidone and olanzapine in patients with affective disorders (F3)." | 4.12 | Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. ( Hefner, G; Klimke, A; Reißner, P; Toto, S; Wolff, J, 2022) |
| " Here, we report the case of a 20-year-old man with severe social anxiety disorder, major depressive disorder, insomnia and attenuated psychotic symptoms despite ongoing treatment with cognitive behavioural therapy and mirtazapine who was treated with adjunctive cannabidiol (CBD) in doses between 200 and 800 mg/day for 6 months." | 3.96 | Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. ( Amminger, GP; Berger, M; Li, E, 2020) |
| " He had an ischemic stroke and developed a psychotic condition that was successfully treated by lowering the cabergoline and administering quetiapine and mirtazapine together." | 3.91 | Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report. ( Casulari, LA; de Castro, LF; de Fátima Magalhães Gonzaga, M; Kessler, IM; Mendonça, JL, 2019) |
| "A 40-year old woman with a history of acute psychotic symptoms developed agranulocytosis and neutropenia after starting therapy that included lamotrigine, mirtazapine, quetiapine, and venlafaxine." | 3.78 | Fatal agranulocytosis associated with psychotropic medication use. ( Al-Najjar, T; Ali, BA; Nazer, LH; Shankar, G, 2012) |
| "To our knowledge, this is the second reported case of Status epilepticus that has been associated with the use of olanzapine, while only one report of seizures, but none of Status epilepticus connected to mirtazapine is found in the literature." | 3.75 | Status epilepticus in a patient treated with olanzapine and mirtazapine. ( Iacovides, A; Kaprinis, G; Nimatoudis, J; Sokolaki, S; Spyridi, S, 2009) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "Mirtazapine is an antidepressant with a mechanism that involves activating serotonin (5-HT1) receptors." | 2.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| "However, diagnosis of schizoaffective disorder is included both in DSM-IV-TR and ICD-10." | 2.41 | [Schizoaffective disorder: clinical symptoms and present-day approach to treatment]. ( Danileviciūte, V, 2002) |
| "Mirtazapine is a presynaptic alpha-2 antagonist that has dual action by increasing noradrenergic and serotonergic neurotransmission." | 2.40 | Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. ( Barkin, RL; Fawcett, J, 1998) |
| "The widespread prevalence of coronavirus disease 2019 (COVID-19) means that inpatient psychiatric units will necessarily manage patients who have COVID-19 that is comorbid with acute psychiatric symptoms." | 1.62 | Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment. ( Frankle, WG; Lequesne, E; Rohs, A; Zhang, E, 2021) |
| "Haloperidol was discontinued, but mirtazapine was continued, and the vivid dream activity persisted; however, reality testing when awake was intact." | 1.36 | Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment. ( Felthous, AR; Hoevet, R; Wenger, PJ, 2010) |
| "Priapism is a "persistent erection not accompanied by sexual desire or stimulation, usually lasting more than six hours and typically involving only the corpora cavernosa." | 1.33 | Priapism and quetiapine: a case report. ( Dilley, JW; Harrison, G; Loeb, L; Nelson, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 7 (30.43) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Hefner, G | 1 |
| Wolff, J | 1 |
| Toto, S | 1 |
| Reißner, P | 1 |
| Klimke, A | 1 |
| Berger, M | 1 |
| Li, E | 1 |
| Amminger, GP | 1 |
| Haddad, PM | 1 |
| Al Abdulla, M | 1 |
| Latoo, J | 1 |
| Iqbal, Y | 1 |
| Sasao, A | 1 |
| Yonemitsu, K | 1 |
| Ohtsu, Y | 1 |
| Tsutsumi, H | 1 |
| Furukawa, S | 1 |
| Kimura-Mishima, S | 1 |
| Nishitani, Y | 1 |
| Zhang, E | 1 |
| Lequesne, E | 1 |
| Rohs, A | 1 |
| Frankle, WG | 1 |
| Casulari, LA | 1 |
| de Castro, LF | 1 |
| Kessler, IM | 1 |
| Mendonça, JL | 1 |
| de Fátima Magalhães Gonzaga, M | 1 |
| Vidal, C | 1 |
| Reese, C | 1 |
| Fischer, BA | 1 |
| Chiapelli, J | 1 |
| Himelhoch, S | 1 |
| Tagai, K | 1 |
| Nagata, T | 1 |
| Shinagawa, S | 1 |
| Tsuno, N | 1 |
| Ozone, M | 1 |
| Nakayama, K | 1 |
| Godschalx-Dekker, JA | 1 |
| Siegers, HP | 1 |
| Spyridi, S | 1 |
| Sokolaki, S | 1 |
| Nimatoudis, J | 1 |
| Iacovides, A | 1 |
| Kaprinis, G | 1 |
| Felthous, AR | 1 |
| Wenger, PJ | 1 |
| Hoevet, R | 1 |
| Li, TC | 1 |
| Shiah, IS | 1 |
| Sun, CJ | 1 |
| Tzang, RF | 1 |
| Huang, KC | 1 |
| Lee, WK | 1 |
| Nazer, LH | 1 |
| Shankar, G | 1 |
| Ali, BA | 1 |
| Al-Najjar, T | 1 |
| Danileviciūte, V | 1 |
| Klein, JP | 1 |
| Fiedler, U | 1 |
| Appel, H | 1 |
| Quante, A | 1 |
| Jockers-Scherübl, MC | 1 |
| Harrison, G | 1 |
| Dilley, JW | 1 |
| Loeb, L | 1 |
| Nelson, K | 1 |
| Mutschler, J | 1 |
| Czell, D | 1 |
| Kaps, M | 1 |
| Manzl, G | 1 |
| Fawcett, J | 1 |
| Barkin, RL | 1 |
| Birkenhäger, TK | 1 |
| Moleman, P | 2 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Moustgaard, G | 1 |
| Poyurovsky, M | 1 |
| Weizman, A | 1 |
| Bruijn, JA | 1 |
| Mulder, PG | 1 |
| van den Broek, WW | 1 |
5 reviews available for mirtazapine and Psychoses
| Article | Year |
|---|---|
Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Therapy, Combination; Humans; Mianserin | 2015 |
Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Electroconvulsive Therapy; Fema | 2011 |
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].
Topics: Adolescent; Amisulpride; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic | 2002 |
Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Clinical T | 1998 |
[Two new antidepressants: mirtazapine and venlafaxine].
Topics: Adrenergic alpha-Antagonists; Benzamides; Cyclohexanols; Depressive Disorder; Drug Interactions; Fem | 1999 |
1 trial available for mirtazapine and Psychoses
| Article | Year |
|---|---|
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
17 other studies available for mirtazapine and Psychoses
| Article | Year |
|---|---|
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Female; Humans; Male; Mental Disorders | 2022 |
Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol.
Topics: Adult; Cannabidiol; Cognitive Behavioral Therapy; Depressive Disorder, Major; Depressive Disorder, T | 2020 |
Brief psychotic disorder associated with quarantine and mild COVID-19.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; COVID-19; Humans; Lorazepam; Ma | 2020 |
High blood mirtazapine concentration in a newborn - A case of suspected postpartum infanticide.
Topics: Adult; Chromatography, Liquid; Depression, Postpartum; Female; Forensic Medicine; Homicide; Humans; | 2021 |
Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment.
Topics: Adult; Alcoholism; Antidepressive Agents; Antipsychotic Agents; Clozapine; COVID-19; COVID-19 Nuclei | 2021 |
Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
Topics: Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; | 2019 |
Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
Topics: Aged, 80 and over; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Female; Halluc | 2013 |
Reduction of parkinsonism and psychosis with mirtazapine: a case report.
Topics: Aged; Histamine H1 Antagonists; Humans; Male; Mianserin; Mirtazapine; Parkinsonian Disorders; Psycho | 2014 |
Status epilepticus in a patient treated with olanzapine and mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Female; | 2009 |
Acute psychosis associated with dissociated sleep-wakefulness state after mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Depressive Disorder, Major; Dreams; Ha | 2010 |
Fatal agranulocytosis associated with psychotropic medication use.
Topics: Adult; Agranulocytosis; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Ag | 2012 |
Massive creatine kinase elevations with quetiapine: report of two cases.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Creatine Kinase; Depressive Disorder, | 2006 |
Priapism and quetiapine: a case report.
Topics: Amphetamine; Amphetamine-Related Disorders; Antipsychotic Agents; Comorbidity; Depressive Disorder; | 2006 |
[Psychotic symptoms in a case of locked-in syndrome].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Brain Stem; Cerebral Hemorrhage; Delusions; | 2006 |
Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium.
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Drug Therapy, Combin | 2000 |
Mirtazapine for neuroleptic-induced akathisia.
Topics: Adrenergic alpha-Antagonists; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Haloperidol; Hum | 2001 |
Treatment of mood-congruent psychotic depression with imipramine.
Topics: Adolescent; Adult; Affect; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Im | 2001 |